Lipid mediator n-3 docosapentaenoic acid-derived protectin D1 enhances synaptic inhibition of hippocampal principal neurons by interaction with a G-protein-coupled receptor

Epilepsy is a severe neurological disease manifested by spontaneous recurrent seizures due to abnormal hyper-synchronization of neuronal activity. Epilepsy affects about 1% of the population and up to 40% of patients experience seizures that are resistant to currently available drugs, thus highlighting an urgent need for novel treatments. In this regard, anti-inflammatory drugs emerged as potential therapeutic candidates. In particular, specific molecules apt to resolve the neuroinflammatory response occurring in acquired epilepsies have been proven to counteract seizures in experimental models, and humans. One candidate investigational molecule has been recently identified as the lipid mediator n-3 docosapentaenoic acid-derived protectin D1 (PD1(n-3DPA)) which significantly reduced seizures, cell loss, and cognitive deficit in a mouse model of acquired epilepsy. However, the mechanisms that mediate the PD1(n-3DPA) effect remain elusive. We here addressed whether PD1(n-3DPA) has direct effects on neuronal activity independent of its anti-inflammatory action. We incubated, therefore, hippocampal slices with PD1(n-3DPA) and investigated its effect on excitatory and inhibitory synaptic inputs to the CA1 pyramidal neurons. We demonstrate that inhibitory drive onto the perisomatic region of the pyramidal neurons is increased by PD1(n-3DPA), and this effect is mediated by pertussis toxin-sensitive G-protein coupled receptors. Our data indicate that PD1(n-3DPA) acts directly on inhibitory transmission, most likely at the presynaptic site of inhibitory synapses as also supported by Xenopus oocytes and immunohistochemical experiments. Thus, in addition to its anti-inflammatory effects, PD1(n-3DPA) anti-seizure and neuroprotective effects may be mediated by its direct action on neuronal excitability by modulating their synaptic inputs.

Automated summary

Epilepsy is a severe neurological disease that affects about 1% of the population. Current drug treatments are ineffective for up to 40% of patients, highlighting the need for novel therapies. A molecule called PD1(n-3DPA) has been found to reduce seizures, cell loss, and cognitive deficits in a mouse model of epilepsy. Additionally, PD1(n-3DPA) may directly affect neuronal activity by modulating synaptic inputs.